STOCK TITAN

Delcath Systems to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Delcath Systems, Inc. (Nasdaq: DCTH) announced CEO Gerard Michel's participation in a fireside chat at the Lytham Partners 2024 Investor Select Conference, along with virtual one-on-one meetings with investors. The webcasted fireside chat will take place on February 1, 2024, and the webcast will be available for replay. Management will also be participating in virtual one-on-one meetings throughout the event.
Positive
  • None.
Negative
  • None.

NEW YORK, Jan. 23, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that Gerard Michel, CEO, will participate in a fireside chat moderated by Bill Maughan Ph.D., Senior Analyst at Canaccord Genuity, at the Lytham Partners 2024 Investor Select Conference. Management will also host virtual one-on-one meetings with investors.

Company Webcast

The webcasted fireside chat will take place at 8:45 AM ET on Thursday, February 1, 2024. The webcast can be accessed at https://wsw.com/webcast/lytham10/dcth/2073328 or on the Company's website at delcath.com. The webcast will also be available for replay following the event.

1x1 Meetings

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register for the event at https://lythampartners.com/select2024invreg/.

Further information on the conference is available at https://lythampartners.com/select2024.

About Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (melphalan for Injection/Hepatic Delivery System), approved for use in the United States by FDA, and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion, designated under the medical device regulation for use in Europe and the United Kingdom, are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure.

Contact:

Investor Relations Contact:
Ben Shamsian
Lytham Partners
646-829-9701
shamsian@lythampartners.com

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/delcath-systems-to-participate-in-a-fireside-chat-at-the-lytham-partners-2024-investor-select-conference-302041094.html

SOURCE Delcath Systems, Inc.

FAQ

When is the webcasted fireside chat taking place?

The webcasted fireside chat will take place at 8:45 AM ET on Thursday, February 1, 2024.

Where can the webcast be accessed?

The webcast can be accessed at https://wsw.com/webcast/lytham10/dcth/2073328 or on the Company's website at delcath.com.

How can investors arrange a one-on-one meeting with management?

To arrange a meeting with management, investors can contact Lytham Partners at 1x1@lythampartners.com or register for the event at https://lythampartners.com/select2024invreg.

Where can further information on the conference be found?

Further information on the conference is available at https://lythampartners.com/select2024.

Delcath Systems Inc

NASDAQ:DCTH

DCTH Rankings

DCTH Latest News

DCTH Stock Data

138.39M
21.10M
3.21%
27.87%
3.68%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
QUEENSBURY

About DCTH

delcath systems, inc. (nasdaq- dcth) is a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers. our proprietary product---melphalan hydrochloride for injection for use with the delcath hepatic delivery system (melphalan/hds)---is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure. delcath is in late-stage clinical development in the united states with initial commercial activities in europe, where the melphalan/hds is marketed as a ce marked device under the trade name delcath hepatic chemosat® delivery system for melphalan (chemosat). our commercial strategy for chemosat is to steadily grow clinical adoption in major european markets and utilize physician experience to support appeals for reimbursement. since launch over 250 chemosat treatments have been performed at over 20 leading european cancer centers. in 2016, we launched our focus pivotal study in hepatic dominant ocular